SSY Group ( (HK:2005) ) has issued an update.

SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register its Choline Fenofibrate Sustained-release Capsules (135mg), classified as a type 4 chemical drug and recognized as having passed consistency evaluation. The product is designed for adults with severe hypertriglyceridemia, primary hypercholesterolemia or mixed dyslipidemia, positioning the group to expand its presence in next-generation lipid-lowering treatments and potentially strengthen its competitiveness in the high-end cardiovascular therapeutics segment.

Unlike traditional fenofibrate, the choline fenofibrate formulation offers a direct effect, reduced liver and kidney burden, no dietary restrictions, and safe combination with statins, features that may enhance its clinical adoption and differentiate it in the market. The announcement signals ongoing progress in SSY Group’s product pipeline, informing shareholders and potential investors of a new revenue opportunity and underscoring the company’s strategy to build a stronger portfolio in specialized cardiovascular care within China’s regulated drug market.

The most recent analyst rating on (HK:2005) stock is a Buy
with a HK$5.00 price target.
To see the full list of analyst forecasts on SSY Group stock,
see the HK:2005 Stock Forecast page.